Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pancreatic vascular isolation chemotherapy with AVAS for unresectable pancreatic adenocarcinoma
ACTRN12614000452695Phase 2Withdrawn
- Sponsor
- Professor Rodney J Lane
- Start
- Jun 2018
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gemcitabine and oxaliplatin in pancreatic adenocarcinoma (PDAC), sponsored by Professor Rodney J Lane. Primary endpoint: Response rate of pancreatic tumors. Planned start Jun 2018; status: withdrawn.
02
Drugs
gemcitabineoxaliplatin
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on ACTRN12614000452695.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12614000452695.